Immunotherapy targeting the PD-L1/PD-1 immune checkpoint has shown significant efficacy in solid tumors, including melanoma and non-small-cell lung cancer (NSCLC) 4, 5. Here, CD274 is linked to non-small cell lung carcinoma.